GRAND CAYMAN, Cayman Island--(BUSINESS WIRE)--Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) Monday reported interim results from the ongoing Phase 2 COURAGE study evaluating semaglutide and trevogrumab with or without garetosmab for the ...

Climb Bio, Inc. stays a Buy on budoprutug pMN data; Phase 2 PrisMN readout 2H 2026 + SLE/ITP upside and 2028 cash runway.

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a phase 2 study. The U.K.-based pharma had been evaluating the antisense ...

The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Dr. Jeremie Calais discussing a review of phase 1/2 compounds recently published. Without question, there ...

91.5% of patients experienced a reduction in tumors and a disease control rate of 96.7%; nearly half the patients evaluated remain on treatment Low discontinuation rate due to adverse events of 4% ...